

PHARMACOVIGILANCE PROGRAMME OF INDIA (PvPI)

PvPI TRAINING MODULE

**Indian Pharmacopoeia Commission,
National Coordination Centre – PvPI
Ministry of Health & Family Welfare
Government of India
Sector-23, Raj Nagar, Ghaziabad (U.P.)-201002.**

TABLE OF CONTENTS

		Page
1	Introduction to Pharmacovigilance	1
1.1	Glossary of Terminologies	1
1.1.1	Absolute risk	1
1.1.2	Adverse Event (AE)	1
1.1.3	Adverse (Drug) Reaction (ADR)	1
1.1.4	Allopathy	1
1.1.5	Association	1
1.1.6	Attributable risk	1
1.1.7	Biological products	1
1.1.8	Causal relationship	2
1.1.9	Causality assessment	2
1.1.9	Caveat document	2
1.1.11	Cem-Flow	2
1.1.12	Clinical trial	2
1.1.13	Cohort Event Monitoring	2
1.1.14	Compliance	2
1.1.15	Control group	2
1.1.16	Critical terms	3
1.1.17	Data mining	3
1.1.18	De-challenge	3
1.1.19	Disproportionality analysis	3
1.1.20	Effectiveness/risk	3
1.1.21	Efficacy	3
1.1.22	Epidemiology	4
1.1.23	Essential medicines	4
1.1.24	Excipients	4
1.1.25	Formulary	4
1.1.26	Frequency of ADRs	4
1.1.27	Generic (multisource product)	4
1.1.28	Harm	5
1.1.29	Herbal medicine	5
1.1.30	Homeopathy	5
1.1.31	Information component (IC)	5
1.1.32	Incidence	5
1.1.33	Individual Case Safety Report (ICSR)	5
1.1.34	MedDRA	5
1.1.35	Medical error	5
1.1.36	Member countries	6

TABLE OF CONTENTS

		Page
1.1.37	National Pharmacovigilance centres	6
1.1.38	Odds	6
1.1.39	Odds ratio	6
1.1.40	Omega (δ)	6
1.1.41	OTC (Over the Counter) medicine	6
1.1.42	Pani-Flow	6
1.1.43	Periodic Safety Update Report (PSUR)	6
1.1.44	Pharmacoepidemiology	7
1.1.45	Pharmacology	7
1.1.46	Pharmacovigilance	7
1.1.47	Phocomelia	7
1.1.48	Phytotherapy	7
1.1.49	Placebo	7
1.1.50	Polypharmacy	7
1.1.51	Post-marketing	7
1.1.52	Predisposing factors	7
1.1.53	Pre-marketing	7
1.1.54	Prescription Event Monitoring (PEM)	8
1.1.55	Prescription Only Medicine (POM)	8
1.1.56	Prevalence	8
1.1.57	Prophylaxis	8
1.1.58	Rational drug use	8
1.1.59	Re-challenge	8
1.1.60	Record linkage	8
1.1.61	Reference risk	8
1.1.62	Regulatory authority	9
1.1.63	Relative risk	9
1.1.64	Risk	9
1.1.65	Serious Adverse Event or Reaction	9
1.1.66	Side effect	9
1.1.67	Signal	9
1.1.68	Summary of Product Characteristics (SPC)	9
1.1.69	Spontaneous reporting	10
1.1.70	Thalidomide	10
1.1.71	Traditional medicines	10
1.1.72	Unexpected adverse reaction	10
1.1.73	Vigi-Base	10
1.1.74	Vigi-Flow	10
1.1.75	Vigi-med	10
1.1.76	Vigi-Mine	11

TABLE OF CONTENTS

		Page
1.1.77	Vigi-Search	11
1.1.78	WHO-ART	11
1.1.79	WHO Drug Dictionary (WHO DD)	11
1.2	Why Pharmacovigilance?	12
1.3	What are the major aims of Pharmacovigilance?	12
1.4	Terms commonly used in Pharmacovigilance	12
2	Concepts and Definitions	13
2.1	Pharmacovigilance	13
2.2	Risk Benefit	13
2.3	Adverse Event (or Adverse Experience)	14
2.4	Adverse Drug Reaction (ADR)	15
2.5	Serious of Adverse Event or Adverse Drug Reaction	15
2.6	Severity Vs Seriousness	16
2.7	Causality	16
2.7.1	Why causality assessment?	17
2.7.2	The WHO-UMC causality assessment system	17
2.8	Expectedness	19
2.9	SUSAR	19
2.10	Outcome of Adverse Event	19
2.11	Sources of Report	20
2.11.1	Individual reporting	20
2.11.2	Comprehensive monitoring	20
2.11.3	Population monitoring	20
2.11.4	Other sources	21
2.12	Valid Report	21
2.13	Expedited reporting Vs Periodic reporting	22
2.14	Day zero	23
2.15	Other Drug related issues	23
2.15.1	Medication Errors	23
2.15.2	Misuse	23
2.15.3	Drug Abuse	24
2.15.4	Beneficial effects	24

TABLE OF CONTENTS		
S.No.		Page
3.	Vigi -Flow TRAINING MODULE	25-26
4.	Introduction	27
4.1	System requirements	27
4.2	Limited access version of Vigiflow	27
4.3	Log in	27
4.3.1	Change password	28
4.3.2	Retrieve unsaved report	28
4.3.3	Language	29
4.4	Enter a new report	29
4.5	Send and commit reports within VigiFlow	30
4.6	Edit a committed report	30
5	Enter a new report	31
5.1	Report info page	31
5.1.1	Report information section	31
5.1.2	Information on sender	32
5.1.3	Information on primary source(s)	33
5.2	Patient page	34
5.2.1	Patient characteristics	34-35
5.3	Tests and procedures page	36
5.3.1	Tests	36
5.4	Relevant Medical History Page	37
5.4.1	Relevant medical history . free text	37
5.4.2	Relevant medical history . structured	37
5.5	Relevant past drug therapy	37
5.5.1	Therapy	38
5.6	Reaction page	38
5.6.1	Reaction(s)/event(s) . free text field	38
5.6.2	Reaction / event	38
5.7	Drugs page	39
5.7.1	Suspected drug	40
5.7.2	Concomitant drug	41
6	The causality assessment	41
6.1	VigiFlow is using the WHO causality assessment.	42
7	Assessment page	42
8	Save report	43
9	Send report	43

10	Commit report	45
11	References	46
12	Annexure	
	Suspected ADR Form	

Abbreviations

ACSoMP	Advisory Committee on Safety of Medicinal Products (WHO)
ADE	Adverse drug event/effect
ADR	Adverse drug reaction
AEFI	Adverse event following immunisation
API	Active pharmaceutical ingredient (WHO)
ART	Antiretroviral therapy
ARV	Antiretrovirals
ATC	Anatomical, Therapeutic, Chemical classification
CDC	Centers for Disease Control and Prevention
CDSCO	Central Drugs Standard Control Organization
CEM	Cohort Event Monitoring
CIOMS	Council for International Organizations of Medical Sciences
CRO	Contract research organisation
DDD	Defined Daily Dose
DIA	Drug Information Association
DTC	Direct to consumer
DTP	Direct to patient
E2B	The current international standard for ADR reporting developed by ICH
FIC	(WHO) Family of International Classifications
FOI	Freedom of information
FTP	File transfer protocol
GACVS	Global Advisory Committee on Vaccine Safety (WHO)
GCP	Good clinical practice.
GLP	Good laboratory practice
GMP	Good manufacturing practice
IB	Investigators brochures.
ICD	International Classification of Diseases
ICH	International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
ICSR	Individual case safety report

IPC	Indian Pharmacopoeia Commission
ISO	International Organization for Standardization
ISoP	International Society of Pharmacovigilance
ISPE	International Society for Pharmacoepidemiology
MAH	Market authorisation holder
MedDRA	Medical Dictionary for Drug Regulatory Affairs
NCC	National coordination centre (for pharmacovigilance) Prepared by the Uppsala Monitoring Centre
NCE	New chemical entity
NDA	New Drug Application
NGO	Non-governmental organisation
NME	New molecular entity
NSAID	Non-steroidal anti-inflammatory drug
OTC	Over-the-counter
PCC	Poison Control Centre
PDR	Physicians Desk Reference
PDS	Pharmacoepidemiology and Drug Safety (journal)
PD	Pharmacodynamics
PK	Pharmacokinetics
po	per oral
PEM	Prescription event monitoring
PIL	Package insert leaflet
PMS	Post-marketing surveillance
POM	Prescription only medicine
PPI	Proton Pump Inhibitor
PSM	Procurement and supply management
PSUR	Periodic safety update report
PV	Pharmacovigilance
PvPI	Pharmacovigilance Programme of India
QA	Quality Assurance
QOS	Quality Overall Summary
QSM-WHO	Quality Assurance and Safety of Medicines (WHO)
RCA	Root-cause analysis
SAE	Serious Adverse Event

SAR	Serious Adverse Drug Reaction
SOC	System organ class
SOP	Standard operating procedure
SUSAR	Suspected unexpected serious adverse reaction
UAR	unexpected adverse reaction
UMC	The Uppsala Monitoring Centre
UNITAID	Organization cooperating with WHO and others on the WHO millennium goals
VAERS	Vaccine adverse event reporting system
WHO	World Health Organization
WHO-ART	WHO Adverse Reaction Terminology
WHO-CC	WHO Collaborating Centre, Prepared by the Uppsala Monitoring Centre.
WHO-DD	WHO Drug Dictionary
WHO-DDE	WHO Drug Dictionary Enhanced
WHO-UMC	World Health Organization- Uppsala Monitoring Centre